The Difference Between Biosimilars & Generic Drugs

In the fourth episode of the GHAPP & RhAPP Biosimilar Podcast Series, host Gabriella McCarty, NP, is joined by Tedra Gray, NP, for an in-depth discussion on one of the most common sources of confusion in clinical practice—the differences between biosimilars and generic drugs. As biosimilars become a cornerstone of treatment in gastroenterology and rheumatology, healthcare providers must clearly understand how they differ from traditional generics to ensure accurate patient education and informed clinical decisions.This episode unpacks the fundamental distinctions between biosimilars and generics, including molecular size and structure, complexity of development, and cost of production. While generics are identical copies of small-molecule drugs, biosimilars are highly similar but not identical to biologic medications, requiring an extensive approval process to confirm safety, efficacy, and immunogenicity. With biologic treatments playing a critical role in managing IBD, rheumatoid arthritis, and other chronic inflammatory diseases, understanding these differences is crucial for advanced practice providers (APPs) navigating biosimilar adoption in clinical settings.Throughout the conversation, Gabriella and Tedra discuss key regulatory and clinical aspects of biosimilars, emphasizing how the FDA’s totality of evidence approach ensures their safety and effectiveness. They also address the real-world impact of biosimilars, particularly as insurance-driven transitions become more common. The episode highlights strategies for educating patients, overcoming treatment hesitancy, and advocating for cost-effective, high-quality care while maintaining disease control and remission.With biosimilar adoption expanding, APPs play a vital role in guiding patients through treatment transitions, ensuring they receive the same level of efficacy and safety as with reference biologics. Whether you're an APP, pharmacist, physician, or healthcare professional, this episode provides the knowledge and confidence needed to navigate biosimilar implementation in gastroenterology and rheumatology practice.Stay ahead of the curve—subscribe to GHAPP & RhAPPcast on your favorite podcast platform and download the RhAPP ACE App for expert-driven resources, clinical updates, and continuing education on biosimilars and advanced rheumatology practicePlease take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval